CARBIDOPA ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H14N2O4
Molecular Weight	226.2292
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O

InChI

InChIKey=TZFNLOMSOLWIDK-JTQLQIEISA-N

InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H14N2O4
Molecular Weight	226.2292
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017830s014s016s017s018s019s030lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10934669

Carbidopa is a competitive inhibitor of aromatic L-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) for the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Current evidence indicates that symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson’s disease apparently because it does not cross the blood-brain barrier. However, levodopa, the metabolic precursor of dopamine, does cross the blood- brain barrier, and presumably is converted to dopamine in the brain. When levodopa is administered orally it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. For this reason, large doses of levodopa are required for adequate therapeutic effect and these may often be accompanied by nausea and other adverse reactions, some of which are attributable to dopamine formed in extracerebral tissues. Carbidopa inhibits decarboxylation of peripheral levodopa. Carbidopa has not been demonstrated to have any overt pharmacodynamic actions in the recommended doses.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DOPA decarboxylase 15 Target ID: CHEMBL1843 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11106255	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Idiopathic Parkinson's disease 19 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017830s014s016s017s018s019s030lbl.pdf	Palliative		Approved 8583	LODOSYN Approved Use LODOSYN is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. LODOSYN is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. LODOSYN is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. LODOSYN is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B6), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Launch Date 1977

C_max

Value	Dose	Co-administered	Analyte	Population
108.57 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30295551	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	CARBIDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
559.92 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30295551	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	CARBIDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.09 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30295551	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	CARBIDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
64% DRUG LABEL https://www.drugs.com/monograph/levodopa-carbidopa.html			CARBIDOPA plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BSEP 550 CYP2C19 2057 MRP4 290 MRP3 246 CYP1A2 2153 MRP2 499 P-gp 1741 BCRP 910 CYP19A1 429 CYP2A6 879 CYP2E1 1060 UMAT 30		CYP1B1 71 CYP1A2 832 CYP1A1 151

Drug as perpetrator

Target	Modality	Activity
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=225144194	inconclusive [IC50 11.9877 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=225144194	inconclusive [IC50 30.1116 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/410#sid=11113507	inconclusive [IC50 7.943 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625246#sid=103770731	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625250#sid=103770731	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1325#sid=8139862	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144204461	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/899#sid=11113507	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/891#sid=11113507	no
MRP1 232	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/799#sid=8139862	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1326#sid=8139862	no
UMAT 30	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/602162#sid=93576631	no
AHR 9	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/28963435/	yes
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/28963435/	yes
CYP1A2 2333	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/28963435/	yes
CYP1B1 93	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/28963435/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588834#sid=50104417

PubMed

Title	Date	PubMed
Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.	2003-06-05	12782919
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003-06	12711835
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.	2003-05	12730989
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.	2003-05	12722161
Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl.	2003-04	12698035
[Atypical phenylketonuria treatment effectiveness].	2003-03-15	12637773
Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat.	2003-03	12658372
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.	2003-03	12618057
Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs.	2003-02-14	12586509
Reversal of parkinsonism following liver transplantation.	2003-02-11	12578945
Protein 4.1N is required for translocation of inositol 1,4,5-trisphosphate receptor type 1 to the basolateral membrane domain in polarized Madin-Darby canine kidney cells.	2003-02-07	12444087
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair.	2003-02	12539208
Neonatal dopa-responsive extrapyramidal syndrome in twins with recessive GTPCH deficiency.	2003-01-28	12552057
Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.	2003-01	12441164
Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations.	2003	12706913
Long-term follow-up of L-dopa treatment in children with amblyopia.	2002-12-03	12458842
Semicarbazide-sensitive amine oxidase (SSAO) gene expression in alloxan-induced diabetes in mice.	2002-12	12606817
Levodopa-carbidopa with occlusion in older children with amblyopia.	2002-12	12506278
Effect of promoters on cellular immune response induced by recombinant fowlpox virus expressing multi-epitope polypeptides from HIV-1.	2002-12	12452800
Clozapine withdrawal symptoms in a Parkinson's disease patient.	2002-11	12465085
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.	2002-11	12465054
Effects of entacapone and tolcapone on mitochondrial membrane potential.	2002-10-18	12393055
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.	2002-10	12392583
[The usefulness of dopaminergic drugs in traumatic brain injury].	2002-09-18	12235569
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.	2002-09-15	12223537
The role of PET in localization of neuroendocrine and adrenocortical tumors.	2002-09	12381551
Simultaneous determination of dopa and carbidopa enantiomers by capillary zone electrophoresis.	2002-09	12373770
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.	2002-09	12360545
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.	2002-09	12360537
Olanzapine: a proarrhythmic drug?	2002-09	12355682
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].	2002-08-31	12233164
[Rhabdomyolysis as a complication of Parkinson's disease].	2002-08-08	12165940
Role of adenosine in drug-induced catatonia in mice.	2002-08	12597016
Selegiline: a second look. Six years later: too risky in Parkinson's disease.	2002-08	12199263
Two advances in the management of Parkinson disease.	2002-08	12184472
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.	2002-08	12122189
Levodopa-responsive rubral (Holmes') tremor.	2002-07	12210864
In vivo metabolism and partitioning of 6-[18F]fluoro-L-meta-tyrosine in whole blood: a unified compartment model.	2002-06-07	12108778
[Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa].	2002-06-01	12073510
Gateways to Clinical Trials. June 2002.	2002-06	12168506
Role of sphingosine synthesis inhibition in transcutaneous delivery of levodopa.	2002-05-15	11996809
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.	2002-05-14	12011296
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.	2002-05-01	11980384
Dopaminergic transmission in the rat striatum in vivo in conditions of pharmacological modulation.	2002-04-11	11942697
[Serotonin syndrome: report of a fatal case and review of the literature].	2002-04	12003730
Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.	2002-03	11965836
[Neuroleptic malignant syndrome].	2002	12474710
Restless legs syndrome in the older adult: diagnosis and management.	2002	12390051
[The use of amantadine sulfate in combined therapy of Parkinson's disease].	2002	12161861
Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.	1976-02	1255483

Patents

Sample Use Guides

In Vivo Use Guide

Whether given with carbidopa-levodopa or with levodopa, the optimal daily dose of LODOSYN (CARBIDOPA tablets) must be determined by careful titration. Most patients respond to a 1:10 proportion of carbidopa and levodopa, provided the daily dosage of carbidopa is 70 mg or more a day. The maximum daily dosage of carbidopa should not exceed 200 mg, since clinical experience with larger dosages is limited. If the patient is taking carbidopa-levodopa, the amount of carbidopa in carbidopa-levodopa should be considered when calculating the total amount of LODOSYN to be administered each day.

Route of Administration: Oral

In Vitro Use Guide

It was evaluated the effect of carbidopa on 6-18F-fluoro-3,4-dihydroxy-l-phenylalanine (18F-FDOPA) uptake in the murine β-cell line RIN-m5F. Incubation of RIN-m5F cells with 80 μM carbidopa did not significantly affect the cellular accumulation of 18F-FDOPA.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:56:05 GMT 2025` Edited by `admin` on `Mon Mar 31 17:56:05 GMT 2025`
Record UNII	KR87B45RGH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARBIDOPA ANHYDROUS

Common Name

English

BENZENEPROPANOIC ACID, .ALPHA.-HYDRAZINO-3,4-DIHYDROXY-.ALPHA.-METHYL-, (S)-

Preferred Name

English

carbidopa [INN]

Common Name

English

Carbidopa [WHO-DD]

Common Name

English

CARBIDOPA, L- ANHYDROUS

Common Name

English

CARBIDOPA ANHYDROUS [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C38149